Head-to-head · WeighScore
Kin Meds vs OlleveCare
The verdict
Kin Meds takes it — 72.9/100 to 46.2/100.
Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Kin Meds | OlleveCare |
|---|---|---|
| WeighScore | 72.9/100 | 46.2/100 |
| Grade | C | C |
| Scorecard rank | #75 | #497 |
| Semaglutide | $149/mo (brand Wegovy) | Not disclosed |
| Tirzepatide | $149/mo (brand Zepbound) | Not disclosed |
| Coverage | Coverage not published | 13 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #75 · C
Strengths
- Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
- Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
- LegitScript verified
- Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
- Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health
Where it loses points
- Legal entity name and state of incorporation not publicly disclosed
- The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
- Per-state availability not listed
- $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
- Lab work and dose-titration support not clearly described
Graded #497 · C
Strengths
- 13 states listed explicitly (VA, FL, AZ, MA, HI, IA, MD, NM, WA, KS, NY, DC, ID)
- Both semaglutide and tirzepatide offered — switch molecules without switching platforms
- Multi-service platform — GLP-1, virtual urgent care, and non-controlled refills with one provider
- Cash-pay with a superbill option for out-of-network reimbursement
- Founder Ahmed Emam is named in the footer
Where it loses points
- Legal entity name not disclosed anywhere — can't be verified in a state registry
- Pricing not shown before booking — you must enter the intake flow to see the fee
- Pharmacy partner not named; model appears to fill at your preferred retail pharmacy
- No medical director or prescribing clinician named — only 'board-certified providers'
- No LegitScript badge, BBB profile, or HIPAA/SOC 2 seals displayed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.